Phase II Study Of Single-Agent SU011248 In The Treatment Of Patients With Renal Cell Carcinoma
Phase 2
20 Years
N/A
20 Years
N/A
Not Enrolling
Both
Carcinoma, Renal Cell
Both
Carcinoma, Renal Cell
Trial Information
Phase II Study Of Single-Agent SU011248 In The Treatment Of Patients With Renal Cell Carcinoma
Inclusion Criteria:
- Histologically proven renal cell carcinoma with metastases with a component of clear
cell histology
Exclusion Criteria:
- Any cellular therapy (LAK, TIL, DC), any vaccine therapy, mini-transplantation, or
systemic molecular-targeting therapy for RCC.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Number of Subjects With Objective Response
Outcome Time Frame:
Day 28 of Cycles 1-4
Safety Issue:
No
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
A6181072
NCT ID:
NCT00254540
Start Date:
December 2005
Completion Date:
February 2009
Related Keywords:
- Carcinoma, Renal Cell
- Ph2, RCC, SU011248, SUNITINIB
- Carcinoma
- Carcinoma, Renal Cell
Name | Location |
|---|
